Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Assets: 2020-2025

Historic Assets for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $785.1 million.

  • Mirum Pharmaceuticals' Assets rose 17.55% to $785.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $785.1 million, marking a year-over-year increase of 17.55%. This contributed to the annual value of $670.8 million for FY2024, which is 3.73% up from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' Assets is $785.1 million, which was up 8.17% from $725.8 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' Assets' 5-year high stood at $785.1 million during Q3 2025, with a 5-year trough of $222.2 million in Q1 2021.
  • For the 3-year period, Mirum Pharmaceuticals' Assets averaged around $629.7 million, with its median value being $660.8 million (2024).
  • Data for Mirum Pharmaceuticals' Assets shows a peak YoY soared of 95.47% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Mirum Pharmaceuticals' Assets stood at $294.7 million in 2021, then increased by 19.77% to $352.9 million in 2022, then surged by 83.23% to $646.6 million in 2023, then rose by 3.73% to $670.8 million in 2024, then grew by 17.55% to $785.1 million in 2025.
  • Its last three reported values are $785.1 million in Q3 2025, $725.8 million for Q2 2025, and $690.2 million during Q1 2025.